New combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT03025035
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tested a combination of two drugs—pembrolizumab (an immunotherapy) and olaparib (a PARP inhibitor)—in 14 people with advanced breast cancer that has a BRCA mutation or similar DNA repair problem. The goal was to see if the combo could shrink or stabilize tumors. The cancer in these participants was incurable and had already progressed after other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.